Clinical trials: Pulmonary Disorder, Chronic Obstructive
Pulmonary Disease, Chronic Obstructive
A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)
Studies to date provides substantial evidence for the effectiveness for UMEC 62.5 microgram (mcg) as a long term maintenance therapy for the treatment of COPD; this study further evaluates the efficacy and safety of UMEC 62.5 mcg…
- Trial name
- NCT02184611
- Testing
- Umeclidinium bromide
- Where
- 26 sites in China, South Korea
- Volunteers
- 308 people
- Sponsor
- GlaxoSmithKline
Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT03118765
- Testing
- GSP304 (tiotropium bromide) Inhalation Solution, Spiriva® Respimat® inhalation spray
- Where
- 25 sites in United States
- Volunteers
- 155 people
- Sponsor
- Glenmark Specialty S.A.
Pulmonary Disease, Chronic Obstructive
Drug Use Survey of RESPIMAT in Patients With COPD
To investigate safety and effectiveness information on the use of Tiotropium Respimat for long time of period in daily practical clinical circumstances, and to obtain proper drug use information.
- Trial name
- NCT01145053
- Volunteers
- 361 people
- Sponsor
- Boehringer Ingelheim
COPD, Chronic Obstructive Pulmonary Disease
Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease
The objective of the Biopsy trial is to investigate the effect of roflumilast 500 µg tablets once daily versus placebo on inflammation parameters in bronchial biopsy tissue specimen and additional in sputum and blood serum.
- Trial name
- NCT01509677
- Testing
- Roflumilast
- Where
- 20 sites in Denmark, Germany and 3 more
- Volunteers
- 158 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)
The aim of the study is to compare the efficacy of roflumilast on pulmonary function and symptomatic parameters in patients with chronic obstructive pulmonary disease (COPD) during concomitant administration of salmeterol.
- Trial name
- EOS (NCT00313209)
- Testing
- Roflumilast
- Where
- 134 sites in Austria, Belgium and 8 more
- Volunteers
- 933 people
- Sponsor
- AstraZeneca
COPD
Acupuncture to Enhance for Pulmonary Rehab
The investigator is investigating if acupuncture may improve pulmonary function, exercise tolerance, stress and modulate the inflammatory effects of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT04947800
- Testing
- Pulmonary rehabilitation program + EA Lung Mu-Shu+ St36, Pulmonary rehabilitation program + Lv7/Gb26
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation
The purpose of this study is to evaluate specific alterations in immune cell mechanisms related to neutrophil function as detected by PI3Kdelta-dependent changes in messenger ribonucleic acid (mRNA) extracted from induced sputum…
- Trial name
- NCT02522299
- Testing
- GSK2269557, DISKUS, ELLIPTA
- Where
- 6 sites in Canada, Denmark
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The study assessed the safety and ability of several doses of an orally inhaled medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to improve airflow in the lungs when delivered with an electronic eFlow nebulizer system in…
- Trial name
- NCT02951312
- Testing
- Glycopyrrolate Inhalation Solution 25mg, Glycopyrrolate Inhalation Solution 75mg, Glycopyrrolate Inhalation Solution 200mg
- Volunteers
- 12 people
- Sponsor
- Sunovion Respiratory Development Inc.
Pulmonary Disease, Chronic Obstructive, Major Depression
Treatment of Depressed Chronic Obstructive Pulmonary Disease Patients
Approximately 20% of patients with chronic obstructive pulmonary disease (COPD) have major depression, a condition that contributes to suffering but also to poor treatment adherence leading to increased disability and morbidity.
- Trial name
- NCT00151372
- Testing
- Treatment Adherence Intervention, Enhanced Care
- Where
- 3 sites in United States
- Volunteers
- 141 people
- Sponsor
- Weill Medical College of Cornell University
Pulmonary Disease, Chronic Obstructive
Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
To evaluate COPD-related clinical outcomes and total healthcare utilization in commercially insured (at least 40 years with a subanalysis of those aged 65 years and older) COPD population associated with the use of…
- Trial name
- NCT01331694
- Testing
- fluticasone/salmeterol combination (FSC) 250/50mcg, tiotropium, ipratropium bromide alone or in fixed dose combination with albuterol
- Volunteers
- 76,130 people
- Sponsor
- GlaxoSmithKline
COPD
Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD
The study investigates the effect of 3 days of twice daily treatment of two different doses of RPL554 (a phosphodiesterase [PDE]3/4 inhibitor) or placebo, each administered in addition to once daily tiotropium/olodaterol…
- Trial name
- NCT03673670
- Testing
- RPL554 Suspension, Tiotropium/olodaterol (Respimat)
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 79 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Pulmonary Disease, Chronic Obstructive
Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease
The primary objective of this study is to evaluate long-term safety and patient acceptability of COMBIVENT RESPIMAT Inhalation Spray as compared to the COMBIVENT Inhalation Aerosol Chlorofluorocarbon-Metered Dose Inhaler…
- Trial name
- NCT01019694
- Testing
- Combivent CFC-MDI, Combivent Respimat 20/100 mcg, Atrovent HFA 42 mcg + Albuterol HFA 200 mcg
- Where
- 55 sites in United States
- Volunteers
- 470 people
- Sponsor
- Boehringer Ingelheim
COPD
Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD
Preliminary information from our laboratory indicated that even patients with milder chronic obstructive pulmonary disease (COPD) can have significant physiological derangements which become more pronounced during exercise…
- Trial name
- NCT01491802
- Testing
- LAMA/LABA, LAMA
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- Queen's University
Chronic Obstructive Pulmonary Disease
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects
AZD8871 is a new chemical entity possessing long-acting effect in a single molecule which presents a novel treatment approach to chronic obstructive pulmonary disease [COPD] and potentially also asthma (in combination with an…
- Trial name
- NCT02814656
- Testing
- AZD8871
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Bronchitis
A Trial To Evaluate Two Antibiotics For The Treatment Of Acute Exacerbation Of Chronic Bronchitis (AECB)
This trial is a research drug study to compare the effects of two antibiotics for the treatment of acute exacerbation of chronic bronchitis
- Trial name
- NCT00254566
- Testing
- Moxifloxacin, Azithromycin SR
- Where
- 34 sites in China, Malaysia and 4 more
- Volunteers
- 398 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease, COPD
A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
This study evaluated the safety and efficacy of once and twice daily TD-4208 and placebo when administered using a jet nebulizer for 7 days in a cross-over design to patients with moderate to severe chronic obstructive pulmonary…
- Trial name
- NCT02109172
- Testing
- TD-4208
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Mylan Inc.
Chronic Obstructive Pulmonary Disease
The Use of High Frequency Oscillations With NIV in Hypercapnic COPD Participants
Chronic Obstructive Pulmonary Disease (COPD) is a major cause of chronic morbidity and mortality throughout the world, being the fourth leading cause of death in the world.
- Trial name
- NCT02680639
- Testing
- BiPAP Synchrony ventilator
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Philips Respironics
COPD
Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD
The objectives of the proposed study are to determine 1) the effect of a single dose of Roflumilast on airway blood flow (Qaw) (study period 1) and 2) the effect of long-term Roflumilast treatment on airway blood flow reactivity…
- Trial name
- NCT02097992
- Testing
- Roflumilast
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Miami
COPD, OSA
Validation of the AVAPS AE Algorithm in Chronic Obstructive Pulmonary Disease (COPD) Patients
COPD continues to be a cause of major morbidity for patients. Those patients who also have respiratory failure and obstructive sleep apnoea are at higher risk of exacerbations and death and have worse health related quality of…
- Trial name
- AVAPS-AE (NCT01601977)
- Testing
- AVAPS-AE, Usual care
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Patrick Murphy
Asthma, Chronic Obstructive Pulmonary Disease
Detecting Errors In Using Metered Dose Inhalers (MDI) Among Asthma And Chronic Obstructive Pulmonary Disease (COPD) Patients
Metered Dose Inhaler (MDI) and Dry Powdered Inhaler (DPI) are the two most common devices used to deliver medicine in conditions such as asthma and chronic obstructive pulmonary disease.
- Trial name
- NCT02447575
- Testing
- Education on Use of MDI
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Baylor College of Medicine